Patients in the Pompe Registry who switched from alglucosidase alfa to avalglucosidase alfa: Real-world experience

被引：0
|
作者：
Schoser, B. [1 ]
Abbott, M. [2 ]
Toscano, A. [3 ]
Foster, M. [4 ]
Periquet, M. [5 ]
Sparks, S. [4 ]
Kishnani, P. [6 ]
机构：
[1] LMU Klinikum Munchen, Dept Neurol, Friedrich Baur Inst, Munich, Germany
[2] Baystate Hlth, Springfield, MA USA
[3] Univ Messina, Dept Clin & Expt Med, Reference Ctr Rare Neuromuscular Disorders, Messina, Italy
[4] Sanofi, Cambridge, MA USA
[5] Sanofi, Berlin, Germany
[6] Duke Univ, Med Ctr, Durham, NC USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-394
引用
收藏
页码：572 / 573
页数：2
相关论文
共 50 条
  • [21] Mini-COMET: Safety and efficacy of ≥97 weeks' avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa
    Kronn, David
    Davison, James
    Brassier, Anais
    Broomfield, Alexander
    Hahn, Si Houn
    Kumada, Satoko
    Labarthe, Francois
    Ohki, Hirotaka
    Prakalapakorn, S. Grace
    Haack, Kristina An
    Meng, Xianzhang
    Sparks, Susan
    Tammireddy, Swathi
    Wilson, Catherine
    Zaher, Atef
    Zhou, Tianyue
    Chien, Yin-Hsiu
    Kishnani, Priya
    [J]. GENETICS IN MEDICINE, 2022, 24 (03) : S348 - S349
  • [22] Mini-COMET study: Effects of repeat avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa
    Davison, James
    Brassier, Anais
    Broomfield, Alexander
    Chien, Yin-Hsiu
    Hahn, Si Houn
    Kronn, David
    Kumada, Satoko
    Labarthe, Francois
    Ohki, Hirotaka
    Pichard, Samia
    Prakalapakorn, S. Grace
    Haack, Kristina An
    Johnson, Judith
    Meng, Xianzhang
    Kishnani, Priya S.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S31 - S32
  • [23] Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile -onset Pompe disease: Evidence from real -world experiences
    Chien, Yin-Hsiu
    Tsai, Wen-Hui
    Chang, Chaw-Liang
    Chiu, Pao-Chin
    Chou, Yen-Yin
    Tsai, Fuu-Jen
    Wong, Siew-Lee
    Lee, Ni-Chung
    Hwu, Wuh-Liang
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2020, 23
  • [24] Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa
    Dumitriu, Alexandra
    Lucas, Ann
    Colzani, Raffaella
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2024, 38
  • [25] Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
    Benedikt Schoser
    [J]. BMC Musculoskeletal Disorders, 14 (Suppl 2)
  • [26] Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
    Karagol, Hacer Ilbilge Ertoy
    Inci, Asli
    Terece, Sinem Polat
    Kilic, Ayse
    Demir, Fevzi
    Yapar, Dilek
    Koken, Gizem
    Okur, Ilyas
    Ezgu, Fatih Suheyl
    Tumer, Leyla
    Bakirtas, Arzu
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (04) : 370 - 375
  • [27] Mini-COMET study: Effects of 97 weeks of avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease who were previously treated with alglucosidase alfa
    Kishnani, Priya S.
    Weinert, Marguerite C.
    Davison, James
    Broomfield, Alexander
    Chien, Yin-Hsiu
    Hahn, Sihoun
    Kronn, David
    Kumada, Satoko
    Ohki, Hirotaka
    Pichard, Samia
    Haack, Kristina An
    Tammireddy, Swathi
    Zhou, Tianyue
    Prakalapakorn, Sasapin G.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 74 - 75
  • [28] RESPIRATORY STATUS AT THE TIME OF FIRST TREATMENT WITH ALGLUCOSIDASE ALFA: AN ANALYSIS OF PATIENT DATA FROM THE POMPE REGISTRY
    van der Pleog, A.
    Amartino, H.
    Byrne, B.
    Genge, A.
    Hartung, R.
    Kruijshaar, M.
    Lindberg, C.
    Llerena, J.
    Roberts, M.
    Miller, T.
    Wilson, A.
    Kishnani, P.
    [J]. MUSCLE & NERVE, 2013, 48 (04) : 672 - 673
  • [29] COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses
    Kishnani, P.
    van der Beek, N.
    Haack, K. An
    Armstrong, N.
    Periquet, M.
    Thibault, N.
    Zaher, A.
    Schoser, B.
    [J]. NEUROMUSCULAR DISORDERS, 2023, 33 : S151 - S152
  • [30] Mini-COMET Study: Safety Data and Immunogenicity for Repeat Avalglucosidase Alfa Dosing in Patients with Infantile-onset Pompe Disease who were Previously Treated with Alglucosidase Alfa and Demonstrated Clinical Decline
    Hug, C.
    Chien, Y-H
    Kumada, S.
    Labarthe, F.
    Ohki, H.
    Pichard, S.
    Haack, An S.
    Fraser, P.
    Liu, K.
    Kronn, D.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S123 - S124
12345